MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.
Funding
$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+45Founders
Product
Problem
Current cancer drug development often misses potential biomarkers and novel drug targets, hindering effective patient stratification for oncology treatments. Existing methods lack the accuracy and translatability needed to pinpoint key genetic features with real translational impact.
Solution
MEDiC employs a proprietary CRISPR functional genomics platform integrated with 3D tumor models to identify cancer biomarkers, synthetic lethality targets, and resistance mutations with enhanced precision. This approach systematically assesses the functional contribution of cancer mutations for tumor growth, immune response, and drug response. By combining CRISPR technology with patient tumor-like cancer models, MEDiC aims to improve the accuracy of patient stratification and accelerate the development of novel cancer drugs. The platform is designed to discover key genetic features of cancer that have real translational impacts.
Target Audience
The primary audience includes pharmaceutical companies, oncology researchers, and drug development teams seeking to identify novel drug targets and improve patient stratification in cancer treatment.
Features
- CRISPR functional genomics platform for systematic assessment of cancer mutations.
- 3D tumor models to mimic patient tumors and improve translatability.
- Tumor-immune co-culture system to assess immune response.
- Identification of biomarkers for patient stratification.
- Discovery of synthetic lethality targets for novel drug development.
- Pinpointing resistance mutations to improve treatment strategies.